American Heart Journal
Volume 153, Issue 4 , Pages 621-628 , April 2007

Use of intensified comprehensive cardiac rehabilitation to improve risk factor control in patients with type 2 diabetes mellitus or impaired glucose tolerance—the randomized DANish StUdy of impaired glucose metabolism in the settings of cardiac rehabilitation (DANSUK) study

  • Anne Merete Boas Soja, MD

      Affiliations

    • Bispebjerg University Hospital, Department of Cardiology, Copenhagen, Denmark
    • Corresponding Author InformationReprint requests: Anne Merete Boas Soja, MD, Skovmose Allé 7, Hareskovby, 3500 Vaerloese, Denmark.
    • ,
  • Ann-Dorthe Olsen Zwisler, PhD

      Affiliations

    • Holbaek County Hospital, Holbaek, Denmark
    • ,
  • Marianne Frederiksen, MD

      Affiliations

    • Bispebjerg University Hospital, Department of Cardiology, Copenhagen, Denmark
    • ,
  • Thomas Melchior, PhD

      Affiliations

    • Roskilde County Hospital, Department of Cardiology, Roskilde, Denmark
    • ,
  • Eva Hommel, DMSC

      Affiliations

    • Steno Diabetes Center, Gentofte, Denmark
    • ,
  • Christian Torp-Pedersen, DMSC

      Affiliations

    • Bispebjerg University Hospital, Department of Cardiology, Copenhagen, Denmark
    • ,
  • Mette Madsen, MSc

      Affiliations

    • National Institute of Public Health, Copenhagen, Denmark

Received 1 April 2006 ,Accepted 21 January 2007.

References 

  1. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
  2. Selvin E, Marinopoulos S, Berkenbilt G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141:421–431
  3. Pyorala K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997;20:614–620
  4. Hansson L, Zanchetti A, Carruthers SG, et al. for the HOT Study Group Effect of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet. 1998;351:1755–1762
  5. Heart Outcomes Prevention Evaluation Study Investigators . Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE Study and MICRO-HOPE Substudy. Lancet. 2000;355:253–259
  6. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–393
  7. Olivarius de Fine N, Beck-Nielsen H, Andreasen HA, et al. Randomized controlled trial of structured personal care of type 2 diabetes mellitus. BMJ. 2001;323:1–9
  8. Hanefeld M, Fischer S, Schmechel H, et al. Diabetes Intervention Study. Multiintervention trial in newly diagnosed NIDDM. Diabetes Care. 1991;14:308–317
  9. Rachmani R, Slavachevski I, Berla M, et al. Teaching and motivating patients to control their risk factors retards progression of cardiovascular as well as microvascular sequelae of type 2 diabetes mellitus—a randomized prospective 8 years follow-up study. Diabet Med. 2005;22:410–414
  10. Joss N, Ferguson C, Brown C, et al. Intensified treatment of patients with type 2 diabetes mellitus and overt nephropathy. Q J Med. 2004;97:219–227
  11. Tranche S, Galgo A, Mundet X, et al. on behalf of Karen AP Study Investigators Cardiovascular risk factors in type 2 diabetic patients: multifactorial intervention in primary care. Kidney Int Suppl. 2005;S55–S62
  12. Ménard J, Payette H, Baillargeon J-P, et al. Efficacy of intensive multitherapy for patients with type 2 diabetes mellitus: a randomized controlled trial. Can Med Assoc J. 2005;173:1457–1466
  13. Knowler WC, Barrett-Connor E, Fowler SE, et al. Diabetes Prevention Program Research Group. Reduction in the incidents of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403
  14. Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–1350
  15. Milani RV, Lavie CJ. Behavioral differences and effects of cardiac rehabilitation in diabetic patients following cardiac events. Am J Med. 1996;100:517–523
  16. Banzer JA, Maguire TE, Kennedy CM, et al. Results of cardiac rehabilitation in patients with diabetes mellitus. Am J Cardiol. 2004;93:81–84
  17. Hindman L, Falko JM, LaLonde M, et al. Clinical profile and outcomes of diabetic and nondiabetic patients in cardiac rehabilitation. Am Heart J. 2005;150:1046–1051
  18. Bartnik M, Rydén L, Ferrari R, et al. The prevalence of abnormal glucose regulation in the patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J. 2004;25:1880–1890
  19. Pyörälä K, Lehto S, De Bacquer D, et al. Risk factor management in diabetic and non-diabetic patients with coronary heart disease. Findings from the EUROASPIRE I and II surveys. Diabetologia. 2004;47:1257–1265
  20. Oldridge NB, Guyatt GH, Fischer ME, et al. Cardiac rehabilitation after myocardial infarction. Combined experience of randomized clinical trials. JAMA. 1988;260:945–950
  21. Taylor RS, Brown A, Ebrahim S, et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med. 2004;116:682–692
  22. Zwisler ADO, Schou L, Soja AMB, et al. A randomized clinical trial of hospital-based, comprehendsive cardiac rehabilitation versus usual care for patients with congestive heart failure, ischemic heart disease or high risk of ischemic heart disease (the DANREHAB Trial)—design, intervention and population. Am Heart J. 2005;150:899.e7–899.e16
  23. Soja AMB, Zwisler ADO, Melchior T, et al. Prevalence and characteristics of glucose intolerance in patients referred to cardiac rehabilitation—the DANSUK study. Eur J Cardiovasc Prev Rehabil. 2006;13:784–790
  24. Rehabilitation of people with heart disease—Danish clinical guidelines. Copenhagen, Denmark: Danish Heart Foundation and Danish Society of Cardiology; 1997;
  25. Recommendations by the Working group on Rehabilitation of the European Society of Cardiology . Long-term comprehensive care of cardiac patients. Eur Heart J. 1992;13(Suppl C):1–45
  26. Type 2 diabetes [article online], 2003. Available fromhttp://www.cardiacrehabilitation.dk/rehab_uk/html/index13.html. Accessed 8 January 2007.
  27. American Diabetes Association . Standards of medical care for patients with diabetes mellitus. Clinical practice. Recommendations 2001. Diabetes Care. 2001;24(Suppl 1):S33–S43
  28. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet. 2003;361:2005–2016
  29. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869
  30. Alberti KGMM, Zimmet P. Definitions, diagnosis and classification of diabetes mellitus and its complications: Part 1. Diagnosis and classification of diabetes mellitus—provisional report of a WHO consultation. Diabet Med. 1998;15:539–553
  31. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus . Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183–1197
  32. Myocardial infarction redefined: a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J. 2000;36:959–969
  33. Task force for the Diagnosis and Treatment of Chronic Heart Failure  European Society of Cardiology, Remme WJ, Swedberg K (co-Chairmen). Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 2001;22:1527–1560
  34. Balkau B, Charles MA, Drivsholm T, et al. Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of the insulin resistance syndrome. Diabetes Metab. 2002;28:364–376
  35. Lau C, Færch K, Glümer C, et al. Dietary glycemic index, glycemic load, fiber, simple sugars, and insulin resistance—The Inter99 study. Diabetes Care. 2005;28:1397–1403

 This study obtained financial support from the following institutions: Danish Pharmacy Foundation of 1991, Eva and Henry Frænkel's Memorial Foundation, Copenhagen Hospital Corporation Research Council, The Research Foundation at Bispebjerg University Hospital, Builder LP Christensen's Foundation, and the Danish Heart Foundation.

PII: S0002-8703(07)00089-0

doi: 10.1016/j.ahj.2007.01.030

American Heart Journal
Volume 153, Issue 4 , Pages 621-628 , April 2007

Article Tools

* Image Usage & Resolution